A Phase I Multi-center Study to Evaluate the Safety ,Tolerability and Efficacy of LBL-007 Combined With Toripalimab or LBL-007 Combined With Toripalimab and Axitinib Tablets in the Treatment of Unresectable or Metastatic Melanoma
Latest Information Update: 09 Jan 2024
At a glance
- Drugs Axitinib (Primary) ; LBL-007 (Primary) ; Toripalimab (Primary)
- Indications Acral lentiginous melanoma; Malignant melanoma
- Focus Adverse reactions
- Sponsors Nanjing Leads Biolabs
- 02 Jan 2024 Planned End Date changed from 20 Apr 2024 to 20 Dec 2024.
- 02 Jan 2024 Planned primary completion date changed from 10 Dec 2023 to 10 Aug 2024.
- 30 Jun 2023 According to a BeiGene media release, the study now progressing into phase II stage.